Exploratory biomarker analysis from a phase III study of the PI3K inhibitor copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma: a retrospective study
A retrospective biomarker analysis from a phase III study evaluating the combination of the PI3K inhibitor copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.
Darolutamide in combination with radium-223 exhibits synergistic antitumor efficacy in LNCaP prostate cancer models
A preclinical study demonstrating that the combination of darolutamide and radium-223 shows synergistic antitumor effects in LNCaP prostate cancer models.
First-in-human dose-escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors coexpressing SLFN12 and PDE3A
A first-in-human dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of BAY 2666605, a novel PDE3A-SLFN12 complex inducer, in patients with advanced solid tumors coexpressing SLFN12 and PDE3A.
Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody
A preclinical study investigating BAY 3375968, an Fc-optimized anti-CCR8 antibody, designed to selectively deplete tumor-infiltrating regulatory T cells and enhance antitumor immune responses.